How to use Technologies searched

A search for a company looking for a cancer, preclinical stage, synthetic opportunity would use the selection "Biomedicine, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform technology' in 'Sector' will identify all kinds of searches for technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each search profile gives the name or a short description of the company behind the search, and a link allowing to contact your potential licensee.

Registered users can create non-public notifications profiles which will inform them about new Technologies Searched entries fitting their expertise as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Sunovion is looking for in-licensing opportunities in CNS and respiratory diseases

Organization name

Sunovion Pharmaceuticals Inc.

Profile

In April 2010, DSP's original U.S. subsidiary, Dainippon Sumitomo Pharma America, Inc. (DSPA) was merged into Sepracor. Sunovion is the new company born of this union.

Sunovion is a leading pharmaceutical company dedicated to discovering, developing, and bringing to market therapeutic products that advance the science of medicine to improve the lives of patients, their families, and communities. We specialize in treatments that help people challenged by disorders of the central nervous system and respiratory ailments.

We are developing products with our own internal development programs and collaborating with outside partners on various corporate development and licensing arrangements.

Between our current treatments and the products in our pipeline, Sunovion targets, on the one hand, central nervous system disorder such as schizophrenia, depression, epilepsy, neuropathic pain, and insomnia, and on the other, respiratory conditions such as asthma, allergic rhinitis, and chronic obstructive pulmonary disease (COPD).

Our products are the result of different approaches: our own in-house drug development programs; refining existing products to enhance their safety and efficacy profiles resulting in unique new medicines; along with strategic acquisition and so-called in-licensing of products developed by others.

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries